Targeted therapy for brain tumours: Role of PARP inhibitors

C. Leonetti, A. Biroccio, G. Graziani, L. Tentori

Research output: Contribution to journalArticle

Abstract

The prognosis of malignant glioma and metastatic brain tumours is still extremely poor, despite recent advances in therapeutic strategies with molecular-targeted agents. Poly(ADP-ribose) polymerase (PARP) inhibitors are a promising, novel class of anticancer drugs to be used either as single agents or in combination with chemotherapy and radiotherapy. PARP-1 and PARP-2 are the only PARP proteins that bind to DNA single strand breaks (SSBs), facilitating the repair process by the base excision repair. For this reason, PARPs have been extensively investigated as targets of novel drugs that may be used to enhance the antitumour activity of SSBs inducing agents, such as the methylating compound temozolomide, which is the drug of choice for glioblastoma, or ionizing radiations. Moreover, PARP inhibitors exert cytotoxic effects in monotherapy in BRCA mutated tumours, which are defective in the homologous recombination (HR) repair. Finally, recent studies have shown that inhibition of PARP function might also induce anti-angiogenic effects which might contribute to impair tumour growth. Many clinical trials with PARP inhibitors are ongoing for the treatment of a variety of advanced solid tumours, including primary or secondary brain tumours. This review discusses the implications of targeting PARP on the design of new treatment regimens.

Original languageEnglish
Pages (from-to)218-236
Number of pages19
JournalCurrent Cancer Drug Targets
Volume12
Issue number3
Publication statusPublished - Mar 2012

Fingerprint

Poly(ADP-ribose) Polymerases
Brain Neoplasms
temozolomide
Pharmaceutical Preparations
Recombinational DNA Repair
Single-Stranded DNA Breaks
Neoplasms
Therapeutics
Glioblastoma
Ionizing Radiation
Combination Drug Therapy
Glioma
DNA Repair
Radiotherapy
Clinical Trials
Poly(ADP-ribose) Polymerase Inhibitors
Growth
Proteins

Keywords

  • Angiogenesis
  • Chemoresistance
  • Combination therapy
  • Molecular-targeted therapy
  • Poly(ADP-ribose) polymerase (PARP) inhibitors
  • Telomere
  • Temozolomide
  • Topoisomerase i inhibitors

ASJC Scopus subject areas

  • Drug Discovery
  • Pharmacology
  • Cancer Research

Cite this

Targeted therapy for brain tumours : Role of PARP inhibitors. / Leonetti, C.; Biroccio, A.; Graziani, G.; Tentori, L.

In: Current Cancer Drug Targets, Vol. 12, No. 3, 03.2012, p. 218-236.

Research output: Contribution to journalArticle

@article{ffa90ce8d73340b99b6094ff182283b2,
title = "Targeted therapy for brain tumours: Role of PARP inhibitors",
abstract = "The prognosis of malignant glioma and metastatic brain tumours is still extremely poor, despite recent advances in therapeutic strategies with molecular-targeted agents. Poly(ADP-ribose) polymerase (PARP) inhibitors are a promising, novel class of anticancer drugs to be used either as single agents or in combination with chemotherapy and radiotherapy. PARP-1 and PARP-2 are the only PARP proteins that bind to DNA single strand breaks (SSBs), facilitating the repair process by the base excision repair. For this reason, PARPs have been extensively investigated as targets of novel drugs that may be used to enhance the antitumour activity of SSBs inducing agents, such as the methylating compound temozolomide, which is the drug of choice for glioblastoma, or ionizing radiations. Moreover, PARP inhibitors exert cytotoxic effects in monotherapy in BRCA mutated tumours, which are defective in the homologous recombination (HR) repair. Finally, recent studies have shown that inhibition of PARP function might also induce anti-angiogenic effects which might contribute to impair tumour growth. Many clinical trials with PARP inhibitors are ongoing for the treatment of a variety of advanced solid tumours, including primary or secondary brain tumours. This review discusses the implications of targeting PARP on the design of new treatment regimens.",
keywords = "Angiogenesis, Chemoresistance, Combination therapy, Molecular-targeted therapy, Poly(ADP-ribose) polymerase (PARP) inhibitors, Telomere, Temozolomide, Topoisomerase i inhibitors",
author = "C. Leonetti and A. Biroccio and G. Graziani and L. Tentori",
year = "2012",
month = "3",
language = "English",
volume = "12",
pages = "218--236",
journal = "Current Cancer Drug Targets",
issn = "1568-0096",
publisher = "Bentham Science Publishers B.V.",
number = "3",

}

TY - JOUR

T1 - Targeted therapy for brain tumours

T2 - Role of PARP inhibitors

AU - Leonetti, C.

AU - Biroccio, A.

AU - Graziani, G.

AU - Tentori, L.

PY - 2012/3

Y1 - 2012/3

N2 - The prognosis of malignant glioma and metastatic brain tumours is still extremely poor, despite recent advances in therapeutic strategies with molecular-targeted agents. Poly(ADP-ribose) polymerase (PARP) inhibitors are a promising, novel class of anticancer drugs to be used either as single agents or in combination with chemotherapy and radiotherapy. PARP-1 and PARP-2 are the only PARP proteins that bind to DNA single strand breaks (SSBs), facilitating the repair process by the base excision repair. For this reason, PARPs have been extensively investigated as targets of novel drugs that may be used to enhance the antitumour activity of SSBs inducing agents, such as the methylating compound temozolomide, which is the drug of choice for glioblastoma, or ionizing radiations. Moreover, PARP inhibitors exert cytotoxic effects in monotherapy in BRCA mutated tumours, which are defective in the homologous recombination (HR) repair. Finally, recent studies have shown that inhibition of PARP function might also induce anti-angiogenic effects which might contribute to impair tumour growth. Many clinical trials with PARP inhibitors are ongoing for the treatment of a variety of advanced solid tumours, including primary or secondary brain tumours. This review discusses the implications of targeting PARP on the design of new treatment regimens.

AB - The prognosis of malignant glioma and metastatic brain tumours is still extremely poor, despite recent advances in therapeutic strategies with molecular-targeted agents. Poly(ADP-ribose) polymerase (PARP) inhibitors are a promising, novel class of anticancer drugs to be used either as single agents or in combination with chemotherapy and radiotherapy. PARP-1 and PARP-2 are the only PARP proteins that bind to DNA single strand breaks (SSBs), facilitating the repair process by the base excision repair. For this reason, PARPs have been extensively investigated as targets of novel drugs that may be used to enhance the antitumour activity of SSBs inducing agents, such as the methylating compound temozolomide, which is the drug of choice for glioblastoma, or ionizing radiations. Moreover, PARP inhibitors exert cytotoxic effects in monotherapy in BRCA mutated tumours, which are defective in the homologous recombination (HR) repair. Finally, recent studies have shown that inhibition of PARP function might also induce anti-angiogenic effects which might contribute to impair tumour growth. Many clinical trials with PARP inhibitors are ongoing for the treatment of a variety of advanced solid tumours, including primary or secondary brain tumours. This review discusses the implications of targeting PARP on the design of new treatment regimens.

KW - Angiogenesis

KW - Chemoresistance

KW - Combination therapy

KW - Molecular-targeted therapy

KW - Poly(ADP-ribose) polymerase (PARP) inhibitors

KW - Telomere

KW - Temozolomide

KW - Topoisomerase i inhibitors

UR - http://www.scopus.com/inward/record.url?scp=84857130173&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84857130173&partnerID=8YFLogxK

M3 - Article

C2 - 22268386

AN - SCOPUS:84857130173

VL - 12

SP - 218

EP - 236

JO - Current Cancer Drug Targets

JF - Current Cancer Drug Targets

SN - 1568-0096

IS - 3

ER -